FREMONT, Calif. and SOUTH PLAINFIELD, N.J., Dec. 18, 2014 /PRNewswire/ -- WaferGen Bio-systems, Inc. (NasdaqCM: WGBS) announced today that Admera Health will implement WaferGen's target enrichment technology for next generation sequencing (NGS) as Admera launches PGxOneTM Plus, an expanded version of their proprietary pharmacogenomics test, PGxOneTM.
Dr. Guanghui Hu, Admera Health President, stated, "One of the key challenges in developing clinical-grade targeted next generation sequencing panels is achieving complete coverage of the required genes. Based on our experience, WaferGen's target enrichment technology offers a unique solution that not only provides adequate coverage, but also reduces the number of steps required for sample preparation. This is ideal for our clinical lab setting. The first product to be commercialized through our partnership with WaferGen will be PGxOneTM Plus."
Ivan Trifunovich, President and CEO of WaferGen, noted, "We are pleased that Admera Health has chosen to adopt the Seq-ReadyTM version of our SmartChip TETM system. We believe that SmartChip TETM is the solution of choice for clinical grade NGS sample preparation. We look forward to providing Admera Health unparalleled quality and full support of their needs."
The Seq-ReadyTM TE MultiSample System enables one-step target enrichment and library preparation solution, which addresses CLIA-certified clinical laboratories' significant unmet needs in sequencing-based testing by providing uniform coverage of targeted genes, yielding better test specificity and sensitivity. The superior performance of this new product is based on WaferGen's proprietary technology that relies on massively parallel singleplex PCR, where amplification is cleaner and better controlled, resulting in more accurate test results.
About WaferGen
WaferGen Bio-systems, Inc. is a life science company that offers innovative genomic solutions for clinical testing and research. The SmartChip MyDesignTM Real-Time PCR System is a high-throughput genetic analysis platform for profiling and validating molecular biomarkers via microRNA and mRNA gene expression profiling, as well as single nucleotide polymorphism (SNP) genotyping. The SmartChip TETM System is a novel product offering for target enrichment geared towards clinical Next-Gen sequencing (NGS). The Company also offers the Apollo 324TM product line used in library preparation for NGS. These three complementary technologies offer a powerful set of tools enabling more accurate, faster and cheaper genetic analysis based on Next-Gen Sequencing and Real-Time PCR. For additional information, visit: http://www.wafergen.com
About Admera Health
Admera Health is a molecular diagnostics company focused on personalized medicine. Utilizing advanced genomic technologies and bioinformatics analysis, Admera Health delivers cost-effective clinical diagnostics spanning the continuum of care from its established, CLIA-certified, CAP-accredited laboratory. Admera Health is a GENEWIZ company. For more information, please visit www.admerahealth.com.
Contact:
For WaferGen:
Michael Wood
LifeSci Advisors, LLC
mwood@lifesciadvisors.com
Tel: 646-597-6983
Admera Health
Brady Millican
Brady.millican@admerahealth.com
Tel: 863-670-0928
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/advanced-molecular-diagnostics-company-admera-health-implements-wafergens-next-generation-sequencing-sample-prep-platform-for-clinical-testing-300011647.html
SOURCE WaferGen Bio-systems, Inc.
